Achieve Life Sciences

ACHV

시가총액 US$6.58억

SEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointment of Kaitlyn (Kait) Tuson as Senior Vice President, Marketing and Communications. Tuson joins Achieve's executive team and will lead its marketing, brand strategy, and corporate communications as the Company prepares for the potential commercialization of cytisinicline.

SEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that its board of directors approved stock option grants to purchase an aggregate of 46,500 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 44,500 shares of its common stock for four new employees. Achieve also announced that the board of directors approved an inducement award grant to Benjamin Halladay, the Company's newly appointed Chief Financial Officer, consisting of an option to purchase up to 200,000 shares of common stock and 200,000 RSUs.

Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline Brings public company CFO experience across commercial pharma and business development as Achieve prepares for potential commercialization of cytisinicline

SEATTLE and VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that new data evaluating the efficacy of 52 weeks of cytisinicline treatment for cigarette smoking and e-cigarette cessation will be presented at CHEST 2026, held October 18-21 in Phoenix, Arizona.

Achieve Life Sciences is rated a 'buy' as it nears a second NDA resubmission after resolving prior manufacturing issues. ACHV's FDA setback was manufacturing-related, not efficacy or safety, with two successful Phase 3 trials and over 1,500 exposures supporting its profile. ACHV is well-capitalized, holding $188 million in cash post-private placement, sufficient to fund the NDA resubmission and initial launch activities.

Achieve Life Sciences is navigating a manufacturing reset for cytisinicline following a Complete Response Letter citing facility compliance, not efficacy or safety concerns. I remain bullish on ACHV, contingent on resolving manufacturing issues and leveraging a funded transition to commercialization, not market expansion or first-line displacement. ACHV's cash runway, bolstered by $180M upfront financing, appears sufficient through potential FDA approval in 1H 2027, but dilution and arbitration risks must be monitored.

SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve's board of directors approved stock option grants to purchase an aggregate of 315,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 283,000 shares of its common stock for 7 new employees under Achieve's 2024 Equity Inducement Plan.

SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointments of Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. Both executives bring decades of leadership across pharmaceutical manufacturing, supply chain, and quality.

SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve's board of directors approved stock option grants to purchase an aggregate of 1,190,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 125,000 shares of its common stock for six new employees under Achieve's 2024 Equity Inducement Plan. The stock options have an exercise price equal to the closing price of Achieve's common stock on the grant date.

Achieve Life Sciences NASDAQ: ACHV held its 2026 Annual Meeting of Stockholders virtually, with Chief Executive Officer Andrew Goldberg serving as chairperson of the meeting. Goldberg called the meeting to order and said Erik Atkisson, the company's Chief Legal Officer, would act as secretary and record the minutes.